A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Amazon has curated a section to help find more affordable items on sale this Prime Day as it has an under £50 and under £15 ...

Top-line results for the last cohort of patients in the Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) in 4Q 2025, where we have already demonstrated the ...

Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...

Dental plaque is a complex biofilm at the heart of oral disease. Learn how it causes cavities and gum inflammation and why ...

Skin cancer is the most common type of cancer in the U.S., and it has increased dramatically in the last 50 years. Melanoma, ...